Valuation: Immutep Limited

Market Cap 35.37M 24.9M 22.34M 20.65M 18.71M 34.95M 2.37B 247M 98.36M 1.24B 93.44M 91.46M 3.94B P/E 2027 *
-1.41x
P/E 2028 * -2.18x
Enterprise Value -19.23M -13.54M -12.15M -11.23M -10.17M -19M -1.29B -134M -53.48M -675M -50.8M -49.73M -2.14B EV / Sales 2027 *
-4.81x
EV / Sales 2028 * 0.51x
Free-Float
96.87%
Yield 2027 *
-
Yield 2028 * -
1 day-4.17%
1 week+4.55%
Current month-32.35%
1 month-32.35%
3 months-51.06%
6 months-63.49%
Current year-94.46%
1 week 0.02
Extreme 0.022
0.03
1 month 0.02
Extreme 0.022
0.04
Current year 0.02
Extreme 0.022
0.47
1 year 0.02
Extreme 0.022
0.47
3 years 0.02
Extreme 0.022
0.48
5 years 0.02
Extreme 0.022
0.71
10 years 0.02
Extreme 0.022
0.72
Manager TitleAgeSince
Chief Executive Officer 53 2014-07-08
Director of Finance/CFO - 2018-02-28
Chief Tech/Sci/R&D Officer - 2025-06-30
Director TitleAgeSince
Director/Board Member 53 2014-07-08
Chairman 76 2017-11-16
Director/Board Member 71 2022-09-12
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Exercice

Director

-388,889 0.0264%
10/1/26 Exercice

Director

388,889 0.0264%
3/18/26 Other

Chief Technology Officer

14,224,374 0.9652%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%+4.55%-92.33%-92.81% 22.8M
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
-2.42%-0.13%+23.56%-10.50% 23.36B
Average +3.07%-0.39%+37.89%+136.51% 38.05B
Weighted average by Cap. +2.86%+0.19%+48.03%+160.99%

Financials

2027 *2028 *
Net sales 4M 2.82M 2.53M 2.34M 2.12M 3.95M 268M 27.93M 11.12M 140M 10.57M 10.34M 446M 3M 2.11M 1.89M 1.75M 1.59M 2.96M 201M 20.95M 8.34M 105M 7.93M 7.76M 334M
Net income -30.92M -21.76M -19.53M -18.05M -16.35M -30.55M -2.07B -216M -85.98M -1.08B -81.67M -79.95M -3.44B -28M -19.71M -17.68M -16.35M -14.81M -27.66M -1.88B -195M -77.85M -982M -73.96M -72.4M -3.12B
Net Debt -54.6M -38.44M -34.49M -31.88M -28.88M -53.95M -3.66B -381M -152M -1.92B -144M -141M -6.08B -33.83M -23.82M -21.37M -19.76M -17.89M -33.43M -2.27B -236M -94.09M -1.19B -89.38M -87.49M -3.77B
Projected Income Statement - Annual - Immutep Limited
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
26-10-29 A$0.0230 -4.17% 2,804,679
26-10-28 A$0.0240 +9.09% 4,766,810
26-10-27 A$0.0220 -4.35% 7,379,385
26-10-26 A$0.0230 0.00% 833,486
26-10-23 A$0.0230 +4.55% 554,119
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Immutep Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.0240AUD
Average target price
0.1133AUD
Spread / Average Target
+372.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immutep Limited